{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:52Z","timestamp":1793814112135,"version":"4.6.1"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Warsaw","id":[{"id":"https:\/\/ror.org\/04p2y4s44","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Few millions of new cancer cases are diagnosed worldwide every year. Due to significant progress in understanding cancer biology and developing new therapies, the mortality rates are decreasing with many of patients that can be completely cured. However, vast majority of them require chemotherapy which comes with high medical costs in terms of adverse events, of which cardiotoxicity is one of the most serious and challenging. Anthracyclines (doxorubicin, epirubicin) are a class of cytotoxic agents used in treatment of breast cancer, sarcomas, or hematological malignancies that are associated with high risk of cardiotoxicity that is observed in even up to 30% of patients and can be diagnosed years after the therapy. The mechanism, in which anthracyclines cause cardiotoxicity are not well known, but it is proposed that dysregulation of renin-angiotensin-aldosterone system (RAAS), one of main humoral regulators of cardiovascular system, may play a significant role. There is increasing evidence that drugs targeting this system can be effective in the prevention and treatment of anthracycline-induced cardiotoxicity what has recently found reflection in the recommendation of some scientific societies. In this review, we comprehensively describe possible mechanisms how anthracyclines affect RAAS and lead to cardiotoxicity. Moreover, we critically review available preclinical and clinical data on use of RAAS inhibitors in the primary and secondary prevention and treatment of cardiac adverse events associated with anthracycline-based chemotherapy.<\/jats:p>","DOI":"10.1007\/s10741-020-09977-1","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:07:49Z","timestamp":1590797269000},"page":"295-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-1626","authenticated-orcid":false,"given":"Pawe\u0142","family":"Sobczuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-4009","authenticated-orcid":false,"given":"Magdalena","family":"Czerwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-8450","authenticated-orcid":false,"given":"Marcin","family":"Kleibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-4447","authenticated-orcid":false,"given":"Agnieszka","family":"Cudnoch-J\u0119drzejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"issue":"9","key":"9977_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","volume":"90","author":"RM Damiani","year":"2016","unstructured":"Damiani RM, Moura DJ, Viau CM, Caceres RA, Henriques JAP, Saffi J (2016) Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol 90(9):2063\u20132076. https:\/\/doi.org\/10.1007\/s00204-016-1759-y","journal-title":"Arch Toxicol"},{"key":"9977_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcha.2015.11.004","volume":"10","author":"MA Mitry","year":"2016","unstructured":"Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc 10:17\u201324. https:\/\/doi.org\/10.1016\/j.ijcha.2015.11.004","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"1","key":"9977_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"36","key":"9977_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Group ESD (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"issue":"1","key":"9977_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/jco.2001.19.1.191","volume":"19","author":"LC Kremer","year":"2001","unstructured":"Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19(1):191\u2013196. https:\/\/doi.org\/10.1200\/jco.2001.19.1.191","journal-title":"J Clin Oncol"},{"key":"9977_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, Abilash VG, Tirupathi Pichiah PB, Arunachalam S (2018) Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. Eur J Pharmacol 818:241\u2013253. https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.043","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"9977_CR7","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P","volume":"55","author":"AU Buzdar","year":"1985","unstructured":"Buzdar AU, Marcus C, Smith TL, Blumenschein GR (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55(12):2761\u20132765","journal-title":"Cancer"},{"issue":"5","key":"9977_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710\u2013717","journal-title":"Ann Intern Med"},{"issue":"11","key":"9977_CR9","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"12","key":"9977_CR10","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23(12):2629\u20132636. https:\/\/doi.org\/10.1200\/JCO.2005.12.121","journal-title":"J Clin Oncol"},{"issue":"12","key":"9977_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/nejm199103213241205","volume":"324","author":"SE Lipshultz","year":"1991","unstructured":"Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324(12):808\u2013815. https:\/\/doi.org\/10.1056\/nejm199103213241205","journal-title":"N Engl J Med"},{"issue":"13","key":"9977_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/nejm199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900\u2013905. https:\/\/doi.org\/10.1056\/nejm199809243391307","journal-title":"N Engl J Med"},{"issue":"13","key":"9977_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/jco.2010.33.4730","volume":"30","author":"HJ van der Pal","year":"2012","unstructured":"van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC (2012) High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30(13):1429\u20131437. https:\/\/doi.org\/10.1200\/jco.2010.33.4730","journal-title":"J Clin Oncol"},{"issue":"23","key":"9977_CR14","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","volume":"65","author":"GT Armstrong","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, Griffin BP, Grimm RA, Thomas J, Phelan D, Collier P, Krull KR, Mulrooney DA, Green DM, Hudson MM, Robison LL, Plana JC (2015) Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 65(23):2511\u20132522. https:\/\/doi.org\/10.1016\/j.jacc.2015.04.013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9977_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF00253110","volume":"2","author":"A Trouet","year":"1979","unstructured":"Trouet A, Deprez-De Campeneere D (1979) Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data. Cancer Chemother Pharmacol 2(1):77\u201379","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"9977_CR16","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/sj.onc.1208627","volume":"24","author":"YW Eom","year":"2005","unstructured":"Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G, Choi KS (2005) Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24(30):4765\u20134777. https:\/\/doi.org\/10.1038\/sj.onc.1208627","journal-title":"Oncogene"},{"issue":"4673","key":"9977_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","volume":"226","author":"KM Tewey","year":"1984","unstructured":"Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673):466\u2013468","journal-title":"Science"},{"issue":"1","key":"9977_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","volume":"1132","author":"G Capranico","year":"1992","unstructured":"Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F (1992) Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1132(1):43\u201348","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"9977_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","volume":"61","author":"T Simunek","year":"2009","unstructured":"Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61(1):154\u2013171","journal-title":"Pharmacol Rep"},{"issue":"7","key":"9977_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727\u2013741","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"9977_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","volume":"23","author":"JM Berthiaume","year":"2007","unstructured":"Berthiaume JM, Wallace KB (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23(1):15\u201325. https:\/\/doi.org\/10.1007\/s10565-006-0140-y","journal-title":"Cell Biol Toxicol"},{"issue":"7","key":"9977_CR22","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","volume":"261","author":"KJ Davies","year":"1986","unstructured":"Davies KJ, Doroshow JH (1986) Redox cycling of anthracyclines by cardiac mitochondria. I Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261(7):3060\u20133067","journal-title":"J Biol Chem"},{"issue":"2","key":"9977_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/jci72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124(2):617\u2013630. https:\/\/doi.org\/10.1172\/jci72931","journal-title":"J Clin Invest"},{"issue":"2","key":"9977_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6","journal-title":"Pharmacol Rev"},{"issue":"7","key":"9977_CR25","first-page":"1789","volume":"60","author":"OJ Arola","year":"2000","unstructured":"Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60(7):1789\u20131792","journal-title":"Cancer Res"},{"issue":"6","key":"9977_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00005-009-0051-8","volume":"57","author":"YW Zhang","year":"2009","unstructured":"Zhang YW, Shi J, Li YJ, Wei L (2009) Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 57(6):435\u2013445. https:\/\/doi.org\/10.1007\/s00005-009-0051-8","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"2","key":"9977_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1474-9726.2007.00358.x","volume":"7","author":"Y Maejima","year":"2008","unstructured":"Maejima Y, Adachi S, Ito H, Hirao K, Isobe M (2008) Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7(2):125\u2013136. https:\/\/doi.org\/10.1111\/j.1474-9726.2007.00358.x","journal-title":"Aging Cell"},{"issue":"2","key":"9977_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/circulationaha.109.895771","volume":"121","author":"A De Angelis","year":"2010","unstructured":"De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121(2):276\u2013292. https:\/\/doi.org\/10.1161\/circulationaha.109.895771","journal-title":"Circulation"},{"issue":"1\u20132","key":"9977_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","volume":"255","author":"E Martin","year":"2009","unstructured":"Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjornelund J, Sehested M, Jensen LH (2009) Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 255(1\u20132):72\u201379. https:\/\/doi.org\/10.1016\/j.tox.2008.10.011","journal-title":"Toxicology"},{"issue":"11","key":"9977_CR30","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642. https:\/\/doi.org\/10.1038\/nm.2919","journal-title":"Nat Med"},{"issue":"11","key":"9977_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD (2010) The renin\u2013angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745\u2013759. https:\/\/doi.org\/10.1038\/nrc2945","journal-title":"Nat Rev Cancer"},{"key":"9977_CR32","doi-asserted-by":"publisher","unstructured":"Singh KD, Karnik SS (2016) Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal 1(2). https:\/\/doi.org\/10.4172\/jcs.1000111","DOI":"10.4172\/jcs.1000111"},{"issue":"2\u20133","key":"9977_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0014-5793(92)80071-n","volume":"298","author":"N Iwai","year":"1992","unstructured":"Iwai N, Inagami T (1992) Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 298(2\u20133):257\u2013260. https:\/\/doi.org\/10.1016\/0014-5793(92)80071-n","journal-title":"FEBS Lett"},{"issue":"17","key":"9977_CR34","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.2174\/1381612811319170012","volume":"19","author":"Y Uehara","year":"2013","unstructured":"Uehara Y, S-i M, Yahiro E, Saku K (2013) Non-ACE pathway-induced angiotensin II production. Curr Pharm Des 19(17):3054\u20133059","journal-title":"Curr Pharm Des"},{"issue":"3","key":"9977_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0895-7061(95)00349-5","volume":"9","author":"H Urata","year":"1996","unstructured":"Urata H, Nishimura H, Ganten D (1996) Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 9(3):277\u2013284. https:\/\/doi.org\/10.1016\/0895-7061(95)00349-5","journal-title":"Am J Hypertens"},{"issue":"4","key":"9977_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00005344-199,704,000-00004","volume":"29","author":"Q Li","year":"1997","unstructured":"Li Q, Feenstra M, Pfaffendorf M, Eijsman L, van Zwieten PA (1997) Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J Cardiovasc Pharmacol 29(4):451\u2013456. https:\/\/doi.org\/10.1097\/00005344-199,704,000-00004","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"9977_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0303-7207(92)90101-b","volume":"90","author":"G Aguilera","year":"1992","unstructured":"Aguilera G (1992) Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol 90(1):53\u201360. https:\/\/doi.org\/10.1016\/0303-7207(92)90101-b","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"9977_CR38","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1161\/01.cir.89.5.2273","volume":"89","author":"B Schieffer","year":"1994","unstructured":"Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89(5):2273\u20132282. https:\/\/doi.org\/10.1161\/01.cir.89.5.2273","journal-title":"Circulation"},{"issue":"6","key":"9977_CR39","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1046\/j.1523-1755.2002.00365.x","volume":"61","author":"G Wolf","year":"2002","unstructured":"Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F (2002) Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61(6):1986\u20131995. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00365.x","journal-title":"Kidney Int"},{"issue":"3","key":"9977_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.res.73.3.413","volume":"73","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73(3):413\u2013423. https:\/\/doi.org\/10.1161\/01.res.73.3.413","journal-title":"Circ Res"},{"issue":"3","key":"9977_CR41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/01.hyp.32.3.496","volume":"32","author":"K Yamada","year":"1998","unstructured":"Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM (1998) Converting enzyme determines plasma clearance of angiotensin-(1\u20137). Hypertension 32(3):496\u2013502. https:\/\/doi.org\/10.1161\/01.hyp.32.3.496","journal-title":"Hypertension"},{"issue":"43","key":"9977_CR42","doi-asserted-by":"publisher","first-page":"39721","DOI":"10.1074\/jbc.M105253200","volume":"276","author":"S AbdAlla","year":"2001","unstructured":"AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U (2001) The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276(43):39721\u201339,726. https:\/\/doi.org\/10.1074\/jbc.M105253200","journal-title":"J Biol Chem"},{"issue":"21","key":"9977_CR43","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1007\/s00018-004-4246-1","volume":"61","author":"SY Chai","year":"2004","unstructured":"Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL (2004) The angiotensin IV\/AT4 receptor. Cell Mol Life Sci 61(21):2728\u20132737. https:\/\/doi.org\/10.1007\/s00018-004-4246-1","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"9977_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0167-0115(96)02116-7","volume":"68","author":"EA Kramar","year":"1997","unstructured":"Kramar EA, Harding JW, Wright JW (1997) Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 68(2):131\u2013138. https:\/\/doi.org\/10.1016\/s0167-0115(96)02116-7","journal-title":"Regul Pept"},{"issue":"2","key":"9977_CR45","doi-asserted-by":"publisher","first-page":"F290","DOI":"10.1152\/ajprenal.1998.274.2.F290","volume":"274","author":"RK Handa","year":"1998","unstructured":"Handa RK, Krebs LT, Harding JW, Handa SE (1998) Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol 274(2):F290\u2013F299. https:\/\/doi.org\/10.1152\/ajprenal.1998.274.2.F290","journal-title":"Am J Physiol"},{"key":"9977_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.peptides.2016.03.017","volume":"79","author":"BM Park","year":"2016","unstructured":"Park BM, Cha SA, Lee SH, Kim SH (2016) Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats. Peptides 79:66\u201374. https:\/\/doi.org\/10.1016\/j.peptides.2016.03.017","journal-title":"Peptides"},{"issue":"5","key":"9977_CR47","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.res.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res 87(5):E1\u2013E9. https:\/\/doi.org\/10.1161\/01.res.87.5.e1","journal-title":"Circ Res"},{"key":"9977_CR48","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2119\/molmed.2015.00022","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Li B, Wang X, Li G, Shang R, Yang J, Wang J, Zhang M, Chen Y, Zhang Y, Zhang C, Hao P (2015) Angiotensin-(1\u20137) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II type 1 receptor, angiotensin II type 2 receptor and Mas receptor. Mol Med 21:626\u2013636. https:\/\/doi.org\/10.2119\/molmed.2015.00022","journal-title":"Mol Med"},{"issue":"9","key":"9977_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.13742","volume":"174","author":"SS Karnik","year":"2017","unstructured":"Karnik SS, Singh KD, Tirupula K, Unal H (2017) Significance of angiotensin 1\u20137 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br J Pharmacol 174(9):737\u2013753. https:\/\/doi.org\/10.1111\/bph.13742","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9977_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0006-8993(94)91171-1","volume":"665","author":"MA Fontes","year":"1994","unstructured":"Fontes MA, Silva LC, Campagnole-Santos MJ, Khosla MC, Guertzenstein PG, Santos RA (1994) Evidence that angiotensin-(1\u20137) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res 665(1):175\u2013180. https:\/\/doi.org\/10.1016\/0006-8993(94)91171-1","journal-title":"Brain Res"},{"issue":"1 Pt 2","key":"9977_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/01.hyp.29.1.394","volume":"29","author":"P Li","year":"1997","unstructured":"Li P, Chappell MC, Ferrario CM, Brosnihan KB (1997) Angiotensin-(1\u20137) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29(1 Pt 2):394\u2013400. https:\/\/doi.org\/10.1161\/01.hyp.29.1.394","journal-title":"Hypertension"},{"issue":"12","key":"9977_CR52","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1042\/cs20130436","volume":"126","author":"CA McKinney","year":"2014","unstructured":"McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA (2014) Angiotensin-(1\u20137) and angiotensin-(1\u20139): function in cardiac and vascular remodelling. Clin Sci (Lond) 126(12):815\u2013827. https:\/\/doi.org\/10.1042\/cs20130436","journal-title":"Clin Sci (Lond)"},{"key":"9977_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bcp.2018.08.045","volume":"156","author":"L Gonzalez","year":"2018","unstructured":"Gonzalez L, Novoa U, Moya J, Gabrielli L, Jalil JE, Garcia L, Chiong M, Lavandero S, Ocaranza MP (2018) Angiotensin-(1\u20139) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension. Biochem Pharmacol 156:357\u2013370. https:\/\/doi.org\/10.1016\/j.bcp.2018.08.045","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"9977_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/hjh.0000000000000094","volume":"32","author":"MP Ocaranza","year":"2014","unstructured":"Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, Garcia L, Novoa U, Ayala P, Diaz-Araya G, Godoy I, Chiong M, Lavandero S, Jalil JE, Michea L (2014) Angiotensin-(1\u20139) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme\/Ang II axis. J Hypertens 32(4):771\u2013783. https:\/\/doi.org\/10.1097\/hjh.0000000000000094","journal-title":"J Hypertens"},{"issue":"5","key":"9977_CR55","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/hjh.0b013e328335d291","volume":"28","author":"MP Ocaranza","year":"2010","unstructured":"Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, Gonzalez L, Hernandez C, Varas M, Lopez R, Godoy I, Verdejo H, Chiong M (2010) Angiotensin-(1\u20139) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28(5):1054\u20131064. https:\/\/doi.org\/10.1097\/hjh.0b013e328335d291","journal-title":"J Hypertens"},{"issue":"4","key":"9977_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/07435809709031858","volume":"23","author":"M Kakiki","year":"1997","unstructured":"Kakiki M, Morohashi K, Nomura M, Omura T, Horie T (1997) Expression of aldosterone synthase cytochrome P450 (P450aldo) mRNA in rat adrenal glomerulosa cells by angiotensin II type 1 receptor. Endocr Res 23(4):277\u2013295","journal-title":"Endocr Res"},{"key":"9977_CR57","doi-asserted-by":"publisher","first-page":"1204598","DOI":"10.1155\/2018\/1204598","volume":"2018","author":"A Cannavo","year":"2018","unstructured":"Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F, Gambino G, D\u2019Amico ML, Perna C, Ferrara N, Rengo G, Paolocci N (2018) Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxidative Med Cell Longev 2018:1204598. https:\/\/doi.org\/10.1155\/2018\/1204598","journal-title":"Oxidative Med Cell Longev"},{"issue":"3","key":"9977_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86(3):747\u2013803. https:\/\/doi.org\/10.1152\/physrev.00036.2005","journal-title":"Physiol Rev"},{"issue":"7","key":"9977_CR59","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.peptides.2011.05.012","volume":"32","author":"JL Zhuo","year":"2011","unstructured":"Zhuo JL, Li XC (2011) New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine\/intracellular angiotensin II. Peptides 32(7):1551\u20131565. https:\/\/doi.org\/10.1016\/j.peptides.2011.05.012","journal-title":"Peptides"},{"issue":"10","key":"9977_CR60","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/hjh.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36(10):1953\u20132041. https:\/\/doi.org\/10.1097\/hjh.0000000000001940","journal-title":"J Hypertens"},{"issue":"6","key":"9977_CR61","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70(6):776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025","journal-title":"J Am Coll Cardiol"},{"key":"9977_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pmedr.2016.01.005","volume":"3","author":"SL Ibrahim","year":"2016","unstructured":"Ibrahim SL, Jiroutek MR, Holland MA, Sutton BS (2016) Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey. Prev Med Rep 3:166\u2013170. https:\/\/doi.org\/10.1016\/j.pmedr.2016.01.005","journal-title":"Prev Med Rep"},{"issue":"5","key":"9977_CR63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/0196-9781(93)90063-m","volume":"14","author":"K Kohara","year":"1993","unstructured":"Kohara K, Brosnihan KB, Ferrario CM (1993) Angiotensin(1\u20137) in the spontaneously hypertensive rat. Peptides 14(5):883\u2013891. https:\/\/doi.org\/10.1016\/0196-9781(93)90063-m","journal-title":"Peptides"},{"issue":"S4","key":"9977_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/87014","volume":"27","author":"A Vekris","year":"2001","unstructured":"Vekris A, Godard F, Haaz M-C, Robert J, Bonnet J (2001) Doxorubicin-induced alterations of the gene expression profiles of leukemia cells in culture using cDNA microarrays. Nat Genet 27(S4):44\u201344. https:\/\/doi.org\/10.1038\/87014","journal-title":"Nat Genet"},{"issue":"8","key":"9977_CR65","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1006\/jmcc.1999.0972","volume":"31","author":"RJ Boucek Jr","year":"1999","unstructured":"Boucek RJ Jr, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA (1999) Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31(8):1435\u20131446. https:\/\/doi.org\/10.1006\/jmcc.1999.0972","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"9977_CR66","doi-asserted-by":"publisher","first-page":"e48771","DOI":"10.1371\/journal.pone.0048771","volume":"7","author":"M Zheng","year":"2012","unstructured":"Zheng M, Kang YM, Liu W, Zang WJ, Bao CY, Qin DN (2012) Inhibition of cyclooxygenase-2 reduces hypothalamic excitation in rats with adriamycin-induced heart failure. PLoS One 7(11):e48771. https:\/\/doi.org\/10.1371\/journal.pone.0048771","journal-title":"PLoS One"},{"issue":"11","key":"9977_CR67","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3109\/10715762.2010.509399","volume":"44","author":"W Arozal","year":"2010","unstructured":"Arozal W, Watanabe K, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Suzuki K, Tachikawa H, Kodama M, Aizawa Y (2010) Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats. Free Radic Res 44(11):1369\u20131377. https:\/\/doi.org\/10.3109\/10715762.2010.509399","journal-title":"Free Radic Res"},{"issue":"5","key":"9977_CR68","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/fcp.12054","volume":"28","author":"A Rashikh","year":"2014","unstructured":"Rashikh A, Pillai KK, Najmi AK (2014) Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity. Fundam Clin Pharmacol 28(5):489\u2013500. https:\/\/doi.org\/10.1111\/fcp.12054","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"9977_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1254\/jjp.88.183","volume":"88","author":"K Okumura","year":"2002","unstructured":"Okumura K, Jin D, Takai S, Miyazaki M (2002) Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 88(2):183\u2013188","journal-title":"Jpn J Pharmacol"},{"issue":"1\u20133","key":"9977_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0300-483x(94)90176-7","volume":"92","author":"J Zhang","year":"1994","unstructured":"Zhang J, Herman EH, Ferrans VJ (1994) Effects of ICRF-186 [(l)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. Toxicology 92(1\u20133):179\u2013192. https:\/\/doi.org\/10.1016\/0300-483x(94)90176-7","journal-title":"Toxicology"},{"issue":"1","key":"9977_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/ndt\/gfh579","volume":"20","author":"M Rook","year":"2005","unstructured":"Rook M, Lely AT, Kramer AB, van Goor H, Navis G (2005) Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 20(1):59\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfh579","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"9977_CR72","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcp.25905","volume":"233","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chen JY, Kuo CH, Pai PY, Ho TJ, Chen TS, Tsai FJ, Padma VV, Kuo WW, Huang CY (2018) Mitochondrial ROS-induced ERK1\/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity. J Cell Physiol 233(1):463\u2013475. https:\/\/doi.org\/10.1002\/jcp.25905","journal-title":"J Cell Physiol"},{"issue":"11","key":"9977_CR73","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/aps.2011.96","volume":"32","author":"WN Zong","year":"2011","unstructured":"Zong WN, Yang XH, Chen XM, Huang HJ, Zheng HJ, Qin XY, Yong YH, Cao K, Huang J, Lu XZ (2011) Regulation of angiotensin-(1\u20137) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin 32(11):1345\u20131350. https:\/\/doi.org\/10.1038\/aps.2011.96","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"9977_CR74","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1074\/jbc.M806392200","volume":"284","author":"Y Tateishi","year":"2009","unstructured":"Tateishi Y, Ariyoshi M, Igarashi R, Hara H, Mizuguchi K, Seto A, Nakai A, Kokubo T, Tochio H, Shirakawa M (2009) Molecular basis for SUMOylation-dependent regulation of DNA binding activity of heat shock factor 2. J Biol Chem 284(4):2435\u20132447. https:\/\/doi.org\/10.1074\/jbc.M806392200","journal-title":"J Biol Chem"},{"issue":"4","key":"9977_CR75","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1291\/hypres.25.597","volume":"25","author":"H Toko","year":"2002","unstructured":"Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I (2002) Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 25(4):597\u2013603","journal-title":"Hypertens Res"},{"issue":"2","key":"9977_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s1388-9842(02)00254-4","volume":"5","author":"VG Sharov","year":"2003","unstructured":"Sharov VG, Todor A, Suzuki G, Morita H, Tanhehco EJ, Sabbah HN (2003) Hypoxia, angiotensin II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail 5(2):121\u2013129. https:\/\/doi.org\/10.1016\/s1388-9842(02)00254-4","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"9977_CR77","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00424-016-1875-9","volume":"468","author":"L-P Wang","year":"2016","unstructured":"Wang L-P, Fan S-J, Li S-M, Wang X-J, Gao J-L, Yang X-H (2016) Protective role of ACE2-Ang-(1\u20137)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1\/2 pathway. Pflugers Arch - Eur J Physiol 468(11):2041\u20132051. https:\/\/doi.org\/10.1007\/s00424-016-1875-9","journal-title":"Pflugers Arch - Eur J Physiol"},{"issue":"10","key":"9977_CR78","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/01.cir.101.10.1130","volume":"101","author":"H Kawano","year":"2000","unstructured":"Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA (2000) Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101(10):1130\u20131137. https:\/\/doi.org\/10.1161\/01.cir.101.10.1130","journal-title":"Circulation"},{"issue":"5","key":"9977_CR79","doi-asserted-by":"publisher","first-page":"H1328","DOI":"10.1152\/ajpheart.00538.2010","volume":"299","author":"J Xu","year":"2010","unstructured":"Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, Liu TS, Yang JJ, Reudelhuber TL, Yang XP (2010) Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 299(5):H1328\u2013H1338. https:\/\/doi.org\/10.1152\/ajpheart.00538.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"9977_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10616-014-9748-6","volume":"68","author":"E Taskin","year":"2016","unstructured":"Taskin E, Kindap EK, Ozdogan K, Aycan MB, Dursun N (2016) Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II. Cytotechnology 68(1):33\u201343. https:\/\/doi.org\/10.1007\/s10616-014-9748-6","journal-title":"Cytotechnology"},{"issue":"12","key":"9977_CR81","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.2042-7158.2010.01196.x","volume":"62","author":"W Arozal","year":"2010","unstructured":"Arozal W, Watanabe K, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Suzuki K, Kodama M, Aizawa Y (2010) Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol 62(12):1776\u20131783. https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01196.x","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"9977_CR82","doi-asserted-by":"publisher","first-page":"H2138","DOI":"10.1152\/ajpheart.00112.2004","volume":"287","author":"J Francis","year":"2004","unstructured":"Francis J, Wei SG, Weiss RM, Felder RB (2004) Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. Am J Physiol Heart Circ Physiol 287(5):H2138\u2013H2146. https:\/\/doi.org\/10.1152\/ajpheart.00112.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"Suppl 3","key":"9977_CR83","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1111\/j.1440-1681.1996.tb02821.x","volume":"23","author":"MJ McKinley","year":"1996","unstructured":"McKinley MJ, McAllen RM, Pennington GL, Smardencas A, Weisinger RS, Oldfield BJ (1996) Physiological actions of angiotensin II mediated by AT1 AND AT2 receptors in the brain. Clin Exp Pharmacol Physiol 23(Suppl 3):S99\u2013S104. https:\/\/doi.org\/10.1111\/j.1440-1681.1996.tb02821.x","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"9977_CR84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2826.2001.00597.x","volume":"13","author":"BJ Oldfield","year":"2001","unstructured":"Oldfield BJ, Davern PJ, Giles ME, Allen AM, Badoer E, McKinley MJ (2001) Efferent neural projections of angiotensin receptor (AT1) expressing neurones in the hypothalamic paraventricular nucleus of the rat. J Neuroendocrinol 13(2):139\u2013146","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"9977_CR85","doi-asserted-by":"publisher","first-page":"H227","DOI":"10.1152\/ajpheart.01157.2007","volume":"295","author":"YM Kang","year":"2008","unstructured":"Kang YM, Zhang ZH, Xue B, Weiss RM, Felder RB (2008) Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. Am J Physiol Heart Circ Physiol 295(1):H227\u2013H236. https:\/\/doi.org\/10.1152\/ajpheart.01157.2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"9977_CR86","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1055-9965.EPI-06-0870","volume":"16","author":"LW Jones","year":"2007","unstructured":"Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR (2007) Cardiovascular risk profile of patients with HER2\/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and\/or trastuzumab. Cancer Epidemiol Biomark Prev 16(5):1026\u20131031. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0870","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9977_CR87","doi-asserted-by":"publisher","unstructured":"Rabinovich I, Sebastiao APM, Lima RS, Urban CA, Junior ES, Anselmi KF, Elifio-Esposito S, De Noronha L, Moreno-Amaral AN (2018) Cancer stem cell markers ALDH1 and CD44+\/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem 62(3). https:\/\/doi.org\/10.4081\/ejh.2018.2943","DOI":"10.4081\/ejh.2018.2943"},{"issue":"6","key":"9977_CR88","doi-asserted-by":"publisher","first-page":"e66082","DOI":"10.1371\/journal.pone.0066082","volume":"8","author":"KD Silveira","year":"2013","unstructured":"Silveira KD, Barroso LC, Vieira AT, Cisalpino D, Lima CX, Bader M, Arantes RM, Dos Santos RA, Simoes ESAC, Teixeira MM (2013) Beneficial effects of the activation of the angiotensin-(1\u20137) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS One 8(6):e66082. https:\/\/doi.org\/10.1371\/journal.pone.0066082","journal-title":"PLoS One"},{"issue":"2","key":"9977_CR89","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cvr\/cvx162","volume":"114","author":"R Hullin","year":"2018","unstructured":"Hullin R, Metrich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D (2018) Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovasc Res 114(2):272\u2013281. https:\/\/doi.org\/10.1093\/cvr\/cvx162","journal-title":"Cardiovasc Res"},{"issue":"2","key":"9977_CR90","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/cvr\/cvx078","volume":"114","author":"A Lother","year":"2018","unstructured":"Lother A, Bergemann S, Kowalski J, Huck M, Gilsbach R, Bode C, Hein L (2018) Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Cardiovasc Res 114(2):282\u2013290. https:\/\/doi.org\/10.1093\/cvr\/cvx078","journal-title":"Cardiovasc Res"},{"key":"9977_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.steroids.2014.05.017","volume":"91","author":"S Meinel","year":"2014","unstructured":"Meinel S, Gekle M, Grossmann C (2014) Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators. Steroids 91:3\u201310. https:\/\/doi.org\/10.1016\/j.steroids.2014.05.017","journal-title":"Steroids"},{"issue":"4","key":"9977_CR92","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1755-5922.12189","volume":"34","author":"G Liu","year":"2016","unstructured":"Liu G, Liu Y, Wang R, Hou T, Chen C, Zheng S, Dong Z (2016) Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. Cardiovasc Ther 34(4):216\u2013224. https:\/\/doi.org\/10.1111\/1755-5922.12189","journal-title":"Cardiovasc Ther"},{"issue":"6","key":"9977_CR93","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.HYP.31.6.1290","volume":"31","author":"K Node","year":"1998","unstructured":"Node K, Kitakaze M, Kosaka H, Minamino T, Mori H, Hori M (1998) Role of Ca2+-activated K+ channels in the protective effect of ACE inhibition against ischemic myocardial injury. Hypertension 31(6):1290\u20131298","journal-title":"Hypertension"},{"issue":"5","key":"9977_CR94","first-page":"694","volume":"20","author":"R Ferrari","year":"1992","unstructured":"Ferrari R, Cargnoni A, Curello S, Ceconi C, Boraso A, Visioli O (1992) Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol 20(5):694\u2013704","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"9977_CR95","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0022-2828(87)80619-3","volume":"19","author":"K Li","year":"1987","unstructured":"Li K, Chen X (1987) Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 19(9):909\u2013915","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"9977_CR96","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12013-012-9386-6","volume":"64","author":"YC Zhang","year":"2012","unstructured":"Zhang YC, Tang Y, Zhang M, Chen J, Zhou Q, Sun YG, Chen MT, Xu WP (2012) Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys 64(3):205\u2013211. https:\/\/doi.org\/10.1007\/s12013-012-9386-6","journal-title":"Cell Biochem Biophys"},{"issue":"5","key":"9977_CR97","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1388-9842(02)00091-0","volume":"4","author":"M Vaynblat","year":"2002","unstructured":"Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ 3rd, Cunningham JN Jr, Chiavarelli M (2002) Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 4(5):583\u2013586","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"9977_CR98","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","volume":"142","author":"A Hiona","year":"2011","unstructured":"Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, Wu JC (2011) Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg 142(2):396\u2013403.e393. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.07.097","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1\u20133","key":"9977_CR99","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ejphar.2013.06.040","volume":"714","author":"H Cernecka","year":"2013","unstructured":"Cernecka H, Ochodnicka-Mackovicova K, Kucerova D, Kmecova J, Nemcekova V, Doka G, Kyselovic J, Krenek P, Ochodnicky P, Klimas J (2013) Enalaprilat increases PPARbeta\/delta expression, without influence on PPARalpha and PPARgamma, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. Eur J Pharmacol 714(1\u20133):472\u2013477. https:\/\/doi.org\/10.1016\/j.ejphar.2013.06.040","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"9977_CR100","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jat.782","volume":"21","author":"MA Abd El-Aziz","year":"2001","unstructured":"Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA (2001) Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 21(6):469\u2013473. https:\/\/doi.org\/10.1002\/jat.782","journal-title":"J Appl Toxicol"},{"issue":"1\u20133","key":"9977_CR101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejphar.2003.10.002","volume":"482","author":"AW Scribner","year":"2003","unstructured":"Scribner AW, Loscalzo J, Napoli C (2003) The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 482(1\u20133):95\u201399. https:\/\/doi.org\/10.1016\/j.ejphar.2003.10.002","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"9977_CR102","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/FJC.0b013e3181865f28","volume":"52","author":"C Richard","year":"2008","unstructured":"Richard C, Lauzier B, Delemasure S, Talbot S, Ghibu S, Collin B, Senecal J, Menetrier F, Vergely C, Couture R, Rochette L (2008) Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats. J Cardiovasc Pharmacol 52(3):278\u2013285. https:\/\/doi.org\/10.1097\/FJC.0b013e3181865f28","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"9977_CR103","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1527-3466.1999.tb00008.x","volume":"17","author":"A Subissi","year":"1999","unstructured":"Subissi A, Evangelista S, Giachetti A (1999) Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 17(2):115\u2013133. https:\/\/doi.org\/10.1111\/j.1527-3466.1999.tb00008.x","journal-title":"Cardiovasc Drug Rev"},{"issue":"9","key":"9977_CR104","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/0006-2952(90)90250-O","volume":"40","author":"IT Mak","year":"1990","unstructured":"Mak IT, Freedman AM, Dickens BF, Weglicki WB (1990) Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40(9):2169\u20132175","journal-title":"Biochem Pharmacol"},{"issue":"5\u20136","key":"9977_CR105","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.vph.2009.01.001","volume":"50","author":"G Sacco","year":"2009","unstructured":"Sacco G, Mario B, Lopez G, Evangelista S, Manzini S, Maggi CA (2009) ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vasc Pharmacol 50(5\u20136):166\u2013170. https:\/\/doi.org\/10.1016\/j.vph.2009.01.001","journal-title":"Vasc Pharmacol"},{"issue":"1","key":"9977_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0014-2999(01)00782-8","volume":"414","author":"G Sacco","year":"2001","unstructured":"Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA (2001) Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 414(1):71\u201378","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9977_CR107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2143\/ac.67.1.2146570","volume":"67","author":"E Bozcali","year":"2012","unstructured":"Bozcali E, Dedeoglu DB, Karpuz V, Suzer O, Karpuz H (2012) Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia\/reperfusion injury as well as doxorubicin cardiotoxicity. Acta Cardiol 67(1):87\u201396. https:\/\/doi.org\/10.2143\/ac.67.1.2146570","journal-title":"Acta Cardiol"},{"issue":"23","key":"9977_CR108","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1073\/pnas.1202916109","volume":"109","author":"C Coletta","year":"2012","unstructured":"Coletta C, Papapetropoulos A, Erdelyi K, Olah G, M\u00f3dis K, Panopoulos P, Asimakopoulou A, Ger\u00f6 D, Sharina I, Martin E, Szabo C (2012) Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci 109(23):9161\u20139166. https:\/\/doi.org\/10.1073\/pnas.1202916109","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"9977_CR109","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1096\/fj.06-6270fje","volume":"20","author":"RCO Zanardo","year":"2006","unstructured":"Zanardo RCO, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL (2006) Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20(12):2118\u20132120. https:\/\/doi.org\/10.1096\/fj.06-6270fje","journal-title":"FASEB J"},{"issue":"39","key":"9977_CR110","doi-asserted-by":"publisher","first-page":"15560","DOI":"10.1073\/pnas.0705891104","volume":"104","author":"JW Elrod","year":"2007","unstructured":"Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow C-W, Lefer DJ (2007) Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci 104(39):15560\u201315,565. https:\/\/doi.org\/10.1073\/pnas.0705891104","journal-title":"Proc Natl Acad Sci"},{"key":"9977_CR111","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.phrs.2013.08.003","volume":"76","author":"M Monti","year":"2013","unstructured":"Monti M, Terzuoli E, Ziche M, Morbidelli L (2013) The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis. Pharmacol Res 76:171\u2013181. https:\/\/doi.org\/10.1016\/j.phrs.2013.08.003","journal-title":"Pharmacol Res"},{"issue":"9\u201310","key":"9977_CR112","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1440-1681.1997.tb02119.x","volume":"24","author":"A Maeda","year":"1997","unstructured":"Maeda A, Honda M, Kuramochi T, Tanaka K, Takabatake T (1997) An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol 24(9\u201310):720\u2013726","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"9977_CR113","first-page":"237","volume":"9","author":"IH Bauer","year":"1995","unstructured":"Bauer IH, Reams GP, Wu Z, Lau-Sieckman A (1995) Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 9(4):237\u2013243","journal-title":"J Hum Hypertens"},{"issue":"5","key":"9977_CR114","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43(5):970\u2013976. https:\/\/doi.org\/10.1161\/01.HYP.0000124667.34652.1a","journal-title":"Hypertension"},{"issue":"3","key":"9977_CR115","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijcard.2005.08.061","volume":"110","author":"M Soga","year":"2006","unstructured":"Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu P, Mito S, Kunisaki M, Tachikawa H, Kodama M, Aizawa Y (2006) Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 110(3):378\u2013385. https:\/\/doi.org\/10.1016\/j.ijcard.2005.08.061","journal-title":"Int J Cardiol"},{"issue":"3","key":"9977_CR116","first-page":"382","volume":"60","author":"M Iqbal","year":"2008","unstructured":"Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60(3):382\u2013390","journal-title":"Pharmacol Rep"},{"issue":"5","key":"9977_CR117","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.phrs.2009.05.007","volume":"60","author":"MA Ibrahim","year":"2009","unstructured":"Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR (2009) Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 60(5):373\u2013381. https:\/\/doi.org\/10.1016\/j.phrs.2009.05.007","journal-title":"Pharmacol Res"},{"issue":"8","key":"9977_CR118","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/HJH.0b013e328165d159","volume":"25","author":"J Shao","year":"2007","unstructured":"Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T (2007) Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 25(8):1643\u20131649. https:\/\/doi.org\/10.1097\/HJH.0b013e328165d159","journal-title":"J Hypertens"},{"issue":"3","key":"9977_CR119","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.mehy.2004.09.015","volume":"64","author":"S Yamagishi","year":"2005","unstructured":"Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64(3):476\u2013478. https:\/\/doi.org\/10.1016\/j.mehy.2004.09.015","journal-title":"Med Hypotheses"},{"issue":"6","key":"9977_CR120","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1096\/fj.03-0724rev","volume":"18","author":"S Fogli","year":"2004","unstructured":"Fogli S, Nieri P, Breschi MC (2004) The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 18(6):664\u2013675. https:\/\/doi.org\/10.1096\/fj.03-0724rev","journal-title":"FASEB J"},{"issue":"50","key":"9977_CR121","doi-asserted-by":"publisher","first-page":"47266","DOI":"10.1074\/jbc.M106829200","volume":"276","author":"SV Kalivendi","year":"2001","unstructured":"Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B (2001) Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem 276(50):47266\u201347,276. https:\/\/doi.org\/10.1074\/jbc.M106829200","journal-title":"J Biol Chem"},{"issue":"2\u20133","key":"9977_CR122","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0014-5793(94)00531-1","volume":"347","author":"AW Hahn","year":"1994","unstructured":"Hahn AW, Jonas U, Buhler FR, Resink TJ (1994) Activation of human peripheral monocytes by angiotensin II. FEBS Lett 347(2\u20133):178\u2013180. https:\/\/doi.org\/10.1016\/0014-5793(94)00531-1","journal-title":"FEBS Lett"},{"issue":"2","key":"9977_CR123","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.etap.2013.05.006","volume":"36","author":"AI Matouk","year":"2013","unstructured":"Matouk AI, Taye A, Heeba GH, El-Moselhy MA (2013) Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ Toxicol Pharmacol 36(2):443\u2013450. https:\/\/doi.org\/10.1016\/j.etap.2013.05.006","journal-title":"Environ Toxicol Pharmacol"},{"issue":"1","key":"9977_CR124","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ptr.2008","volume":"21","author":"MR Loizzo","year":"2007","unstructured":"Loizzo MR, Said A, Tundis R, Rashed K, Statti GA, Hufner A, Menichini F (2007) Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Phytother Res 21(1):32\u201336. https:\/\/doi.org\/10.1002\/ptr.2008","journal-title":"Phytother Res"},{"issue":"6","key":"9977_CR125","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1139\/cjpp-2015-0461","volume":"94","author":"HF Sakr","year":"2016","unstructured":"Sakr HF, Abbas AM, Elsamanoudy AZ (2016) Effect of valsartan on cardiac senescence and apoptosis in a rat model of cardiotoxicity. Can J Physiol Pharmacol 94(6):588\u2013598. https:\/\/doi.org\/10.1139\/cjpp-2015-0461","journal-title":"Can J Physiol Pharmacol"},{"issue":"4","key":"9977_CR126","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1354\/vp.44-4-494","volume":"44","author":"H Aupperle","year":"2007","unstructured":"Aupperle H, Garbade J, Schubert A, Barten M, Dhein S, Schoon HA, Mohr FW (2007) Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol 44(4):494\u2013503. https:\/\/doi.org\/10.1354\/vp.44-4-494","journal-title":"Vet Pathol"},{"issue":"4","key":"9977_CR127","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.phrs.2006.01.001","volume":"53","author":"K Kizaki","year":"2006","unstructured":"Kizaki K, Ito R, Okada M, Yoshioka K, Uchide T, Temma K, Mutoh K, Uechi M, Hara Y (2006) Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 53(4):341\u2013346. https:\/\/doi.org\/10.1016\/j.phrs.2006.01.001","journal-title":"Pharmacol Res"},{"issue":"3","key":"9977_CR128","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cardiores.2005.12.009","volume":"69","author":"S Rutschow","year":"2006","unstructured":"Rutschow S, Li J, Schultheiss HP, Pauschinger M (2006) Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 69(3):646\u2013656. https:\/\/doi.org\/10.1016\/j.cardiores.2005.12.009","journal-title":"Cardiovasc Res"},{"issue":"2","key":"9977_CR129","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bjp.0707344","volume":"152","author":"AK Chow","year":"2007","unstructured":"Chow AK, Cena J, Schulz R (2007) Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152(2):189\u2013205. https:\/\/doi.org\/10.1038\/sj.bjp.0707344","journal-title":"Br J Pharmacol"},{"issue":"5","key":"9977_CR130","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3346\/jkms.2015.30.5.559","volume":"30","author":"SA Chang","year":"2015","unstructured":"Chang SA, Lim BK, Lee YJ, Hong MK, Choi JO, Jeon ES (2015) A Novel angiotensin type I receptor antagonist, fimasartan, prevents doxorubicin-induced cardiotoxicity in rats. J Korean Med Sci 30(5):559\u2013568. https:\/\/doi.org\/10.3346\/jkms.2015.30.5.559","journal-title":"J Korean Med Sci"},{"issue":"4","key":"9977_CR131","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","volume":"30","author":"JA Ezekowitz","year":"2009","unstructured":"Ezekowitz JA, McAlister FA (2009) Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 30(4):469\u2013477. https:\/\/doi.org\/10.1093\/eurheartj\/ehn543","journal-title":"Eur Heart J"},{"issue":"2","key":"9977_CR132","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.biopha.2011.11.020","volume":"66","author":"A Rashikh","year":"2012","unstructured":"Rashikh A, Ahmad SJ, Pillai KK, Kohli K, Najmi AK (2012) Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy. Biomed Pharmacother 66(2):138\u2013143. https:\/\/doi.org\/10.1016\/j.biopha.2011.11.020","journal-title":"Biomed Pharmacother"},{"key":"9977_CR133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12947-015-0011-x","volume":"13","author":"G Akolkar","year":"2015","unstructured":"Akolkar G, Bhullar N, Bews H, Shaikh B, Premecz S, Bordun KA, Cheung DY, Goyal V, Sharma AK, Garber P, Singal PK, Jassal DS (2015) The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity. Cardiovasc Ultrasound 13:18. https:\/\/doi.org\/10.1186\/s12947-015-0011-x","journal-title":"Cardiovasc Ultrasound"},{"issue":"18","key":"9977_CR134","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1128\/JVI.01001-12","volume":"86","author":"M Schneider","year":"2012","unstructured":"Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schatzl HM, Gilch S (2012) Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol 86(18):10112\u201310122. https:\/\/doi.org\/10.1128\/JVI.01001-12","journal-title":"J Virol"},{"issue":"1","key":"9977_CR135","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2008.01.043","volume":"134","author":"L Lu","year":"2009","unstructured":"Lu L, Wu W, Yan J, Li X, Yu H, Yu X (2009) Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 134(1):82\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2008.01.043","journal-title":"Int J Cardiol"},{"key":"9977_CR136","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lfs.2016.09.006","volume":"169","author":"L Lai","year":"2017","unstructured":"Lai L, Chen J, Wang N, Zhu G, Duan X, Ling F (2017) MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. Life Sci 169:69\u201375. https:\/\/doi.org\/10.1016\/j.lfs.2016.09.006","journal-title":"Life Sci"},{"issue":"15","key":"9977_CR137","doi-asserted-by":"publisher","first-page":"24548","DOI":"10.18632\/oncotarget.15595","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma H, Kong J, Wang YL, Li JL, Hei NH, Cao XR, Yang JJ, Yan WJ, Liang WJ, Dai HY, Dong B (2017) Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. Oncotarget 8(15):24548\u201324563. https:\/\/doi.org\/10.18632\/oncotarget.15595","journal-title":"Oncotarget"},{"issue":"4","key":"9977_CR138","doi-asserted-by":"publisher","first-page":"624","DOI":"10.4161\/auto.23577","volume":"9","author":"MH Zou","year":"2013","unstructured":"Zou MH, Xie Z (2013) Regulation of interplay between autophagy and apoptosis in the diabetic heart: new role of AMPK. Autophagy 9(4):624\u2013625. https:\/\/doi.org\/10.4161\/auto.23577","journal-title":"Autophagy"},{"issue":"9","key":"9977_CR139","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3727\/096368911X627552","volume":"21","author":"DK Singla","year":"2012","unstructured":"Singla DK, Ahmed A, Singla R, Yan B (2012) Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. Cell Transplant 21(9):1919\u20131930. https:\/\/doi.org\/10.3727\/096368911X627552","journal-title":"Cell Transplant"},{"issue":"6","key":"9977_CR140","doi-asserted-by":"publisher","first-page":"432","DOI":"10.7555\/JBR.26.20120006","volume":"26","author":"D Ren","year":"2012","unstructured":"Ren D, Zhu Q, Li J, Ha T, Wang X, Li Y (2012) Overexpression of angiopoietin-1 reduces doxorubicin-induced apoptosis in cardiomyocytes. J Biomed Res 26(6):432\u2013438. https:\/\/doi.org\/10.7555\/JBR.26.20120006","journal-title":"J Biomed Res"},{"issue":"3","key":"9977_CR141","first-page":"219","volume":"40","author":"HZ Liu","year":"2012","unstructured":"Liu HZ, Gao CY, Wang XQ, Fu HX, Yang HH, Wang XP, Liu YH, Li MW, Niu ZM, Dai GY, Qi DT, Zhang Y (2012) Angiotensin(1\u20137) attenuates left ventricular dysfunction and myocardial apoptosis on rat model of adriamycin-induced dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 40(3):219\u2013224","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"2","key":"9977_CR142","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/HYPERTENSIONAHA.110.164244","volume":"57","author":"J Zhong","year":"2011","unstructured":"Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY (2011) Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57(2):314\u2013322. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.164244","journal-title":"Hypertension"},{"issue":"7","key":"9977_CR143","doi-asserted-by":"publisher","first-page":"e0158537","DOI":"10.1371\/journal.pone.0158537","volume":"11","author":"M Chakrabarti","year":"2016","unstructured":"Chakrabarti M, Klionsky DJ, Ray SK (2016) miR-30e blocks autophagy and acts synergistically with proanthocyanidin for inhibition of AVEN and BIRC6 to increase apoptosis in glioblastoma stem cells and glioblastoma SNB19 cells. PLoS One 11(7):e0158537. https:\/\/doi.org\/10.1371\/journal.pone.0158537","journal-title":"PLoS One"},{"issue":"5","key":"9977_CR144","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1124\/mol.113.090092","volume":"85","author":"H Lin","year":"2014","unstructured":"Lin H, Li HF, Chen HH, Lai PF, Juan SH, Chen JJ, Cheng CF (2014) Activating transcription factor 3 protects against pressure-overload heart failure via the autophagy molecule Beclin-1 pathway. Mol Pharmacol 85(5):682\u2013691. https:\/\/doi.org\/10.1124\/mol.113.090092","journal-title":"Mol Pharmacol"},{"issue":"13","key":"9977_CR145","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900\u20132909. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030","journal-title":"Eur J Cancer"},{"issue":"3","key":"9977_CR146","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/annonc\/mdw671","volume":"28","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee DS, Thavendiranathan P, Tomlinson G (2017) Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol 28(3):628\u2013633. https:\/\/doi.org\/10.1093\/annonc\/mdw671","journal-title":"Ann Oncol"},{"issue":"1081","key":"9977_CR147","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133,535","volume":"91","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 91(1081):627\u2013633. https:\/\/doi.org\/10.1136\/postgradmedj-2015-133,535","journal-title":"Postgrad Med J"},{"key":"9977_CR148","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S (2018) Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy +\/- trastuzumab. Breast 37:64\u201371. https:\/\/doi.org\/10.1016\/j.breast.2017.10.010","journal-title":"Breast"},{"issue":"2","key":"9977_CR149","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-009-0730-5","volume":"122","author":"AH Blaes","year":"2010","unstructured":"Blaes AH, Gaillard P, Peterson BA, Yee D, Virnig B (2010) Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 122(2):585\u2013590. https:\/\/doi.org\/10.1007\/s10549-009-0730-5","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"9977_CR150","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/coc.0000000000000389","volume":"41","author":"S Wittayanukorn","year":"2018","unstructured":"Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA (2018) Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or beta-blockers in older adults with breast cancer. Am J Clin Oncol 41(9):909\u2013918. https:\/\/doi.org\/10.1097\/coc.0000000000000389","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"9977_CR151","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85(11):894\u2013896. https:\/\/doi.org\/10.1002\/ajh.21840","journal-title":"Am J Hematol"},{"issue":"23","key":"9977_CR152","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am College Cardiol 61(23):2355\u20132362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072","journal-title":"J Am College Cardiol"},{"issue":"2","key":"9977_CR153","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J (2017) Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 17(2):130\u2013139. https:\/\/doi.org\/10.1007\/s12012-016-9365-z","journal-title":"Cardiovasc Toxicol"},{"issue":"9","key":"9977_CR154","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911\u2013939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"issue":"23","key":"9977_CR155","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/circulationaha.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474\u20132481. https:\/\/doi.org\/10.1161\/circulationaha.106.635144","journal-title":"Circulation"},{"key":"9977_CR156","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer 94:126\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005","journal-title":"Eur J Cancer"},{"issue":"11","key":"9977_CR157","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali Singh T (2018) Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer 65(11):e27308. https:\/\/doi.org\/10.1002\/pbc.27308","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"9977_CR158","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000492942","volume":"63","author":"M Dlugosz-Danecka","year":"2018","unstructured":"Dlugosz-Danecka M, Gruszka AM, Szmit S, Olszanecka A, Ogorka T, Sobocinski M, Jaroszynski A, Krawczyk K, Skotnicki AB, Jurczak W (2018) Primary cardioprotection reduces mortality in lymphoma patients with increased risk of anthracycline cardiotoxicity, treated by R-CHOP regimen. Chemotherapy 63(4):238\u2013245. https:\/\/doi.org\/10.1159\/000492942","journal-title":"Chemotherapy"},{"issue":"4","key":"9977_CR159","first-page":"1052","volume":"18","author":"D Radulescu","year":"2013","unstructured":"Radulescu D, Buzdugan E, Ciuleanu TE, Todor N, Stoicescu L (2013) Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors? J BUON 18(4):1052\u20131057","journal-title":"J BUON"},{"issue":"5","key":"9977_CR160","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12032-017-0938-x","volume":"34","author":"I Meattini","year":"2017","unstructured":"Meattini I, Curigliano G, Terziani F, Becherini C, Airoldi M, Allegrini G, Amoroso D, Barni S, Bengala C, Guarneri V, Marchetti P, Martella F, Piovano P, Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L (2017) SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Med Oncol 34(5):75. https:\/\/doi.org\/10.1007\/s12032-017-0938-x","journal-title":"Med Oncol"},{"issue":"11","key":"9977_CR161","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","volume":"104","author":"H Nakamae","year":"2005","unstructured":"Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, Yamane T, Hino M (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11):2492\u20132498. https:\/\/doi.org\/10.1002\/cncr.21478","journal-title":"Cancer"},{"issue":"3","key":"9977_CR162","doi-asserted-by":"publisher","first-page":"487 e481","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160(3):487 e481\u2013487 e487. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.037","journal-title":"Am Heart J"},{"issue":"5","key":"9977_CR163","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3892\/etm.2011.305","volume":"2","author":"M Dessi","year":"2011","unstructured":"Dessi M, Piras A, Madeddu C, Cadeddu C, Deidda M, Massa E, Antoni G, Mantovani G, Mercuro G (2011) Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med 2(5):1003\u20131009. https:\/\/doi.org\/10.3892\/etm.2011.305","journal-title":"Exp Ther Med"},{"issue":"1","key":"9977_CR164","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/2193-1801-2-198","volume":"2","author":"M Dessi","year":"2013","unstructured":"Dessi M, Madeddu C, Piras A, Cadeddu C, Antoni G, Mercuro G, Mantovani G (2013) Long-term, up to 18\u00a0months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. SpringerPlus 2(1):198. https:\/\/doi.org\/10.1186\/2193-1801-2-198","journal-title":"SpringerPlus"},{"issue":"9","key":"9977_CR165","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1634\/theoncologist.12-9-1124","volume":"12","author":"G Mercuro","year":"2007","unstructured":"Mercuro G, Cadeddu C, Piras A, Dessi M, Madeddu C, Deidda M, Serpe R, Massa E, Mantovani G (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12(9):1124\u20131133. https:\/\/doi.org\/10.1634\/theoncologist.12-9-1124","journal-title":"Oncologist"},{"issue":"21","key":"9977_CR166","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"key":"9977_CR167","doi-asserted-by":"publisher","unstructured":"Gulati G, Heck SL, Rosjo H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017) Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc 6(11). https:\/\/doi.org\/10.1161\/jaha.117.006513","DOI":"10.1161\/jaha.117.006513"},{"issue":"1","key":"9977_CR168","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17(1):81\u201389. https:\/\/doi.org\/10.1002\/ejhf.196","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"9977_CR169","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.cjca.2016.02.061","volume":"32","author":"MK Davis","year":"2016","unstructured":"Davis MK, Virani SA (2016) Routine prophylactic cardioprotective therapy should not be given to all recipients of potentially cardiotoxic cancer chemotherapy. Can J Cardiol 32(7):926\u2013930. https:\/\/doi.org\/10.1016\/j.cjca.2016.02.061","journal-title":"Can J Cardiol"},{"issue":"8","key":"9977_CR170","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/jco.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35(8):893\u2013911. https:\/\/doi.org\/10.1200\/jco.2016.70.5400","journal-title":"J Clin Oncol"},{"issue":"2","key":"9977_CR171","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"issue":"13","key":"9977_CR172","first-page":"1945","volume":"159","author":"BV Jensen","year":"1997","unstructured":"Jensen BV, Nielsen SL, Jensen TS (1997) Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy. Ugeskr Laeger 159(13):1945\u20131949","journal-title":"Ugeskr Laeger"},{"issue":"3","key":"9977_CR173","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55(3):213\u2013220. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.095","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"9977_CR174","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/jco.2002.12.102","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, Gelber RD, Colan SD (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20(23):4517\u20134522. https:\/\/doi.org\/10.1200\/jco.2002.12.102","journal-title":"J Clin Oncol"},{"issue":"5","key":"9977_CR175","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/annonc\/mdf132","volume":"13","author":"BV Jensen","year":"2002","unstructured":"Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699\u2013709","journal-title":"Ann Oncol"},{"issue":"6","key":"9977_CR176","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00392-018-1386-0","volume":"108","author":"K Ohtani","year":"2019","unstructured":"Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K, Tsutsui H (2019) Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol 108(6):600\u2013611. https:\/\/doi.org\/10.1007\/s00392-018-1386-0","journal-title":"Clin Res Cardiol"},{"key":"9977_CR177","doi-asserted-by":"publisher","unstructured":"Sheppard CE, Anwar M (2018) The use of sacubitril\/valsartan in anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/1078155218783238","DOI":"10.1177\/1078155218783238"},{"key":"9977_CR178","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fcvm.2018.00024","volume":"5","author":"AP Fadol","year":"2018","unstructured":"Fadol AP (2018) Management of chemotherapy-induced left ventricular dysfunction and heart failure in patients with cancer while undergoing cancer treatment: the MD Anderson practice. Front Cardiovasc Med 5:24. https:\/\/doi.org\/10.3389\/fcvm.2018.00024","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"9977_CR179","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73(22):2859\u20132868. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.495","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"9977_CR180","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/ehjci\/jex159","volume":"19","author":"SL Heck","year":"2018","unstructured":"Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storas TH, Ree AH, Gravdehaug B, Rosjo H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018) Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. Eur Heart J Cardiovasc Imaging 19(5):544\u2013552. https:\/\/doi.org\/10.1093\/ehjci\/jex159","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9977_CR181","doi-asserted-by":"publisher","unstructured":"McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK (2015) Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2332","DOI":"10.1158\/1078-0432.CCR-14-2332"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-09977-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09977-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:55:19Z","timestamp":1722952519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-09977-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":181,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["9977"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-09977-1","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"30 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"PS has received travel grants from MSD, Roche and Pierre-Fabre. ACJ, MC, and MK have no conflicts of interest or financial ties to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}